Novel mutations and DNA-based screening in non-Jewish carriers of Tay-Sachs disease

• Published in: American journal of human genetics 1997-05, Vol.60 (5), p.1099-1106
• Main Authors: AKERMAN, B. R, NATOWICZ, M. R, KABACK, M. M, LOYER, M, CAMPEAU, E, GRAVEL, R. A
• Format: Article
• Language: English
• Subjects: beta-N-Acetylhexosaminidases - genetics; Biological and medical sciences; California; Errors of metabolism; Ethnic Groups; Genetic Testing - methods; Heterozygote; Hexosaminidase A; Humans; Lipids (lysosomal enzyme disorders, storage diseases); Massachusetts; Medical sciences; Metabolic diseases; Mutation; Polymerase Chain Reaction; Tay-Sachs Disease - epidemiology; Tay-Sachs Disease - genetics; Tay-Sachs Disease - prevention & control
• ISSN: 0002-9297; 1537-6605

We have evaluated the feasibility of using PCR-based mutation screening for non-Jewish enzyme-defined carriers identified through Tay-Sachs disease-prevention programs. Although Tay-Sachs mutations are rare in the general population, non-Jewish individuals may be screened as spouses of Jewish carriers or as relatives of probands. In order to define a panel of alleles that might account for the majority of mutations in non-Jewish carriers, we investigated 26 independent alleles from 20 obligate carriers and 3 affected individuals. Eighteen alleles were represented by 12 previously identified mutations, 7 that were newly identified, and 1 that remains unidentified. We then investigated 46 enzyme-defined carrier alleles: 19 were pseudodeficiency alleles, and five mutations accounted for 15 other alleles. An eighth new mutation was detected among enzyme-defined carriers. Eleven alleles remain unidentified, despite the testing for 23 alleles. Some may represent false positives for the enzyme test. Our results indicate that predominant mutations, other than the two pseudodeficiency alleles (739C-->T and 745C-->T) and one disease allele (IVS9+1G-->A), do not occur in the general population. This suggests that it is not possible to define a collection of mutations that could identify an overwhelming majority of the alleles in non-Jews who may require Tay-Sachs carrier screening. We conclude that determination of carrier status by DNA analysis alone is inefficient because of the large proportion of rare alleles. Notwithstanding the possibility of false positives inherent to enzyme screening, this method remains an essential component of carrier screening in non-Jews. DNA screening can be best used as an adjunct to enzyme testing to exclude known HEXA pseudodeficiency alleles, the IVS9+1G-->A disease allele, and other mutations relevant to the subject's genetic heritage.